Skip to main content
. 2015 Jul 30;10:155. doi: 10.1186/s13014-015-0470-0

Fig. 2.

Fig. 2

Five-year PCSM among patients with M1a (a), M1b (b), or M2c (c) prostate cancer at diagnosis and conditioned on 5, 10, or 15 years of survival